AVB-S6-500

Phase 2Small molecule

AAravive, Inc.

AVB-S6-500 is one of 143 small molecule programs targeting Fallopian Tube Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

142

Competitors

Pipeline

Status by Indication[3][1]

Indication

Fallopian Tube CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Iga NephropathyActive, not recruiting

Urothelial CarcinomaActive, not recruiting

Fallopian Tube CancerPhase 1

Active, not recruiting

Ovarian CancerPhase 1

Active, not recruiting

Iga NephropathyPhase 2

Active, not recruiting

Urothelial CarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

836 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Femara

Novartis

Phase 3

10 2

Tecentriq

Roche

Phase 3

8 3

Pamiparib

BeiGene

Phase 3

5 4

Trastuzumab Deruxtecan

AstraZeneca

Phase 3

1 5

Defactinib

VVerastem, Inc.

Phase 3

3 6

AK104

AAkeso

Phase 3

2 7

Investigator's Choice of Chemotherapy

CCSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 3

2 8

H1 Receptor Antagonist

Merck & Co.

Phase 3

1 9

Anlotinib Hydrochloride

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

1 10

Single Dose of

Boehringer Ingelheim

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Urothelial Carcinoma

NCT04004442

Clinical

Trials by Indication[1]

Ovarian Cancer1 trial

Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Completed·AAravive, Inc.·Phase 1·NCT03639246·53 enrolled

Phase 11 trial

A Phase 1 AVB-S6-500 Safety and Tolerability Study

Completed·AAravive, Inc.·Phase 1·NCT03401528·43 enrolled

IgA Nephropathy1 trial

Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy

Terminated·AAravive, Inc.·Phase 2·NCT04042623·1 enrolled

Fallopian Tube Cancer1 trial

Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy

Withdrawn·WWashington University School of Medicine·Phase 1·NCT03607955

Urothelial Carcinoma1 trial

Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma

Active, not recruiting·UUniversity of Oklahoma·Phase 1·NCT04004442·19 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for AVB-S6-500. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AVB-S6-500 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AVB-S6-500. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aravive, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAravive, Inc.

AVB-S6-500

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Ovarian Cancer1 trial

Phase 11 trial

IgA Nephropathy1 trial

Fallopian Tube Cancer1 trial

Urothelial Carcinoma1 trial

References

Drug Info

Quick Facts

Related News